Saturday, June 21, 2014

BSD Medical - Brings the Heat


Note:  This report was writtn by a friend of Growth Stock Insider (Tricia Ross of Financial Profiles).  The information was obtained from sources believed to be reliable but are not guaranteed either by the author or Growth Stock Insider.

BSD Medical Corporation (NASDAQ: BSDM) is a pioneer in developing, manufacturing and servicing groundbreaking medical systems to treat cancer using heat therapy.  Its strong competitive position is based on superior technology and product design.  The company is led by a successful, proven management team with a combined 9 decades of Fortune 500 and start-up medical-industry experience. BSD has no debt and an improving bottom line that is moving the company toward profitability.




(Quarterly Revenue)


BSD is poised to benefit from current healthcare trends.  The Company’s systems are closely aligned with the Affordable Care Act’s drive for quality care at lower costs. 

BSD’s MicroThermX® Microwave Ablation System is a transformative opportunity that delivers precision-guided microwave energy to destroy tumors. The MicroThermX is cleared for marketing in the U.S. and many other countries throughout the world. Microwave ablation treatment is less invasive than surgery and effective for certain cancers.

Large and growing market.  The global market for soft tissue microwave ablation is estimated at $510 million and projected to grow 18% annually.  The MicroThermX uses innovative, high-end disposable antennas in each treatment, which can provide significant ongoing revenues with attractive profit margins as the installed base grows.



BSD has an exclusive multi-million dollar distribution agreement with global medical device leader Terumo Corporation to market MicroThermX in 100 countries in Europe, Western Asia and Africa with a market potential that exceeds $1 billion.  Terumo is implementing a well-planned, comprehensive marketing strategy for the MicroThermX that is aimed at geographic expansion and building credibility within the clinical community, resulting in gaining sales traction in the Western European countries. Terumo plans to expand into Eastern European markets with the Middle East to follow. Terumo is also sponsoring several studies with the MicroThermX.

BSD hyperthermia products are designed to increase the effectiveness of primary cancer treatments, such as radiation and chemotherapy by delivering precision-focused microwave or radio frequency energy into diseased sites. BSD’s hyperthermia products are approved in the U.S. and many other countries throughout the world. The Company has exclusive agreements for distribution in Taiwan, South Korea, China and Europe.

Since gaining marketing approval for its hyperthermia products in Taiwan in February 2014, BSD has shipped three BSD-2000 Hyperthermia Systems ordered by its exclusive distributor in that country.  The Company expects to ship a fourth system to Taiwan by its August 31 fiscal year end. 

BSD’s cancer treatment systems have been used to treat thousands of patients throughout the world.  The Company also has received many awards, including the Frost & Sullivan “Technology Innovation of the Year Award” for cancer therapy devices, which was awarded for the development of the BSD-2000 Hyperthermia System.


This blog contains certain forward-looking statements with respect to BSD Medical Corporation.  Forward-looking statements are statements that are not descriptions of historical facts and include statements regarding management's intentions, beliefs, expectations, plans or predictions of the future, within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements include risks, uncertainties and contingencies, actual results may differ materially and in adverse ways from those expressed or implied by such forward-looking statements. Additional information concerning Apollo Medical Holdings, Inc. and its business including additional factors that could materially and adversely affect its financial results including, but not limited to, the risks described in its annual report on Form 10-K and in other filings with the SEC.



Apollo Medical - Nothing but Net


Note:  This is a "guest column" written by a friend of Growth Stock Insider (Jody Cain of Financial Profiles).  The information has been obtained from sources believed to be reliable but it is not guaranteed either bgy the author or Growth Stock Insider.

Apollo Medical Holdings, Inc. (ApolloMed) (AMEH: $0.53) is a leading integrated healthcare services company for patients, hospitals, health plans, physicians and other key healthcare stakeholders. ApolloMed’s mission is to provide high-quality, cost-effective inpatient and outpatient care for all patients with a particular focus on acute, high-risk and senior populations.  In addition to providing hospitalist, ICU and physician advisory services at more than 50 hospitals, facilities and clinics, ApolloMed provides medical management and care coordination for more than 1,000 physicians and tens of thousands of patients through its value-based, results-driven solutions. ApolloMed has been providing the solutions that lead to measureable results for nearly a decade and has core networks in California, Ohio and Mississippi.

ApolloMed is successfully capitalizing on changing healthcare dynamics:  ApolloMed’s goals are aligned with the current industry dynamics of providing high-quality, cost-efficient healthcare services.  Healthcare costs currently top $2.7 trillion in the U.S., representing about 18% of the total U.S. GDP, with more than 50% going to hospitals and physicians.  These costs continue to rise, driven in part by increasing numbers of older Americans who account for high levels of healthcare expenditures, and by more Americans gaining healthcare coverage under the Affordable Care Act.  Fee-for-service healthcare plans lead to inefficiencies based on the absence of a comprehensive, integrated approach.  Health plans are moving away from the fee-for-service framework to a more integrated accountable care model.  ApolloMed has the capability to assume a full range of financial risk offerings.

ApolloMed has a proven ability to grow healthcare networks:  ApolloMed offers inpatient and outpatient solutions and has undergone rapid growth by building networks that include hospitalist services, Accountable Care Organization (ACO), independent physician associations (IPA) and outpatient clinics.  The company is validating its model by developing partnerships with industry leaders, including Fresenius Medical Care for end-stage renal disease and a strategic partnership; Boehringer Ingelheim for COPD chronic care management; and Rite Aid for community-based health treatment for patients with chronic and poly-chronic conditions.

Driving revenues through “Best in Class” medical management and operational efficiencies:  ApolloMed provides the management and data analysis infrastructure to support improved case management and physician-led programs.  The company’s incentive are aligned with physicians and hospitals.  Its financial risk offerings include Low Risk through traditional contract billing or physician staffing through hospitalists services and clinics (more than 80% of fiscal 2014 revenues); shared savings through its ACO, which is a 50/50 split in cost-savings with Medicare (ApolloMed showed a $3.1 million preliminary interim cost savings with potential distribution in 2H14); and partial and full Risk through its IPAs. This is a capitated model with health plans providing a per-member/per-month fee and ApolloMed’s IPA assuming all responsibility for patient care and financials.

ApolloMed is positioned for aggressive growth through its defined strategy.  The company strengthened its balance sheet to support growth through a strategic investment from partner Fresenius Medical Care for up to $12 million announced in April 2014.  The investment includes $2 million in equity at $1 per share, which is 2Xs the current stock price.  The company is focused on strategic acquisitions and partnerships that expand its network and service offerings.  The company is also looking to improve the economics of its ACO and IPA through its increasing scale.  The company has developed a platform and infrastructure that can be replicated in additional geographies. 

ApolloMed is physician led by Chief Executive Officer Warren Hosseinion, M.D., who founded the company with Chief Medical Officer Adrian Vazquez, M.D. in 2001.  Recently the company announced the appointment of Mitchell R. Creem as CFO, who is a seasoned healthcare executive with more than 30 years of industry experience, including CEO for the Keck Hospital of USC and USC Norris Cancer Hospital and Associate Vice Chancellor and Chief Financial Officer for the UCLA Medical Science.  Senior management is rounded by Chief Strategy Officer Mark Meyers, who has more than 30 years of healthcare experience and is the former Senior Vice President of Operations for Dignity Health.

This blog contains certain forward-looking statements with respect to Apollo Medical Holdings, Inc.  Forward-looking statements are statements that are not descriptions of historical facts and include statements regarding management's intentions, beliefs, expectations, plans or predictions of the future, within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements include risks, uncertainties and contingencies, actual results may differ materially and in adverse ways from those expressed or implied by such forward-looking statements. Additional information concerning Apollo Medical Holdings, Inc. and its business including additional factors that could materially and adversely affect its financial results including, but not limited to, the risks described in its annual report on Form 10-K and in other filings with the SEC.